Study of prognostic predictors for non-small cell lung cancer

Lung Cancer

Volumn 23, Issue 2, 1999, Pages 143-152

  Fu, Xiao Long ^a   Zhu, Xiong Zeng ^a   Shi, Da Ren ^a   Xiu, Liang Zhong ^a   Wang, Li Juan ^a   Zhao, Sen ^a   Qian, Hao ^a   Lu, Hong Fen ^a   Xiang, Yong Bing ^b   Jiang, Guo Liang ^a  

^a Minhang Branch   (China)

^b SHANGHAI CANCER INSTITUTE   (China)

Author keywords

Histology; Non small cell lung cancer; Oncoprotein; Prognostic index; Prognostic predictor

Indexed keywords

CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUOROURACIL; ONCOPROTEIN; PROTEIN P53; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033015810     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00009-4     Document Type: Article

References (51)

1. Annual Report of Cancer Incidences (1995). Tumor. 18(3):1998;1-2.
2. Beahrs O.H., Henson D.E., Hutter R.V.P. Manual for Staging of Cancer. 4th ed. 1992;J.B. Lippincott, Philadelphia.
3. Hsu S.M., Raine L., Fanger H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29:1982;577-580.
4. Hespanhol V., Queiroga H., Magalhaes A., Santos A.R., Coelho M., Monques A. Survival predictors in advanced non-small cell lung cancer. Lung. Cancer. 13(3):1995;253-267.
5. Naruke T. Prognostic factors in resected lung cancer: a multivariate regression analysis of 1095 consecutive patients. Karkinos. 6:1993;481-486.
6. Paesmans M., Sculier J.P., Libert P., Bureau G., Pabouis G., Thiriaux J. et al. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J. Clin. Oncol. 13(5):1995;1221-1230.
7. Takigawa N., Segawa Y., Okahara M., Maeda Y., Takata I., Kataoka M. et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung. Cancer. 15(1):1996;67-77.
8. Carbone D.P. The biology of lung cancer. Semin. Oncol. 24(4):1997;388-402.
9. Feld R., Abratt R., Graziano S., Jassem J., Lacquet L., Ninane V. et al. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung. Cancer. 17:1997;S3-S10.
10. Granziano S.L. Non-small cell lung cancer: clinical value of new predictors. Lung. Cancer. 17(Suppl. 1):1997;S37-S59.
11. Cha Q., Chen Y.Z., Du Y.X. The trends in histological types of lung cancer during 1980-1988, Guangzhou, China. Lung. Cancer. 17:1997;219-230.
12. Nesbitt J.C., Putnam J.B., Walsh G.L., Roth J.A., Mountain C.F. Survival in early-stage non-small cell lung cancer. Ann. Thorac. Surg. 60(2):1995;466-472.
13. Rosenthal S.A., Curran W.J. Jr., Herbert S.H., Hughes E.N., Sandler H.M., Stafford P.M. et al. Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease). Cancer. 70:1992;2410-2417.
14. Fu X.L., Jiang G.L., Wang L.J., Qian H., Fu S., Yie M. et al. Discussion of prognostic factors in squamous cell carcinoma and adenocarcinoma of lung treated non-surgically. China. Oncol. 6:1996;199-202.
15. LeChevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Tarayre M. et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung cancer. J. Natl. Cancer. Inst. 83:1991;417-423.
16. Roberts T.E., Hasleton P.S., Musgrove C., Swindell R., Lawson R.A.M. Vascular invasion in non-small cell lung carcinoma. J. Clin. Pathol. 45(7):1992;591-593.
17. Shields T.W. Prognostic significance of parenchymal lymphatic invasion and blood vessel invasion in carcinoma of the lung. Surg. Gynecol. Obstet. 157:1983;185-190.
18. Fildeman A.E., Silvestri G.A., Gatsonis C., Luthringer D., Flyon S.D. Prognostic significance of tumor proliferative fractionated DNA content in stage I non-small cell lung cancer. Am. Rev. Respir. Dis. 146:1992;707-710.
19. Ichinoses Y., Hara N., Ohta M., Motohiro A., Kuda T., Aso H. Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and postrecurrent survival. J. Surg. Oncol. 46:1991;15-20.
20. Yu J., Shaeffer J., Zhu A., Kuban D.A., El-Mahdi A.M., Philput C.B. Flowcytometric DNA content and clinical outcome in patients with non-small cell lung cancer given postoperative radiation therapy. Cytometry. 14:1993;428-432.
21. Fujii M., Moto M., Saeki I., Aoe K., Moriwaki S. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer. Acta. Med. Okayama. 47:1993;103-108.
22. Lequaglie C., Muscoline G., Grignolglio E., Costa A., Silvestrini R., Ravasi G. Stage I lung cancer and cell kinetics. Chest. 98:1990;62S.
23. Harada M., Akita H.D., Dosaka A.H., Miyamoto H., Kuzumiki N., Kawakami Y. Prognostic significance of expression of ras oncogene product expression in non-small cell lung cancer. Cancer. 69:1992;72-77.
24. Kern J.A., Slebos R., Top B., Rodenhuis S., Lager D., Rocinson R.A. et al. c-erb B2 expression and codon 12 k-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest. 93(2):1994;516-520.
25. Miyamoto H., Harada M., Isobe H., Akita H.D., Haneda H., Yamaguchi E. et al. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer. Res. 51:1991;6346-6350.
26. Stahel R.A. Antigens, receptors and dominant oncogenes and the prognosis of non-small cell cancer. Lung. Cancer. 11(Suppl. 3):1994;S31-S38.
27. Volm M., Drings P., Mathern J., Wodrich W. Prognostic value of oncoproteins for the survival of patients with non-small cell lung cancer. Int. J. Oncol. 2:1993;767-772.
28. Giatromanolaki A., Gorgoulis V., Chetty R., Koukouraki M.I., Whitehouse R., Kittas C. et al. C-erb-B-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer. Res. 16(2):1996;987-993.
29. Kawashima K., Nomura S., Hirai H., Fukushi S., Karube T., Takeuchi K. et al. Correlation of L-myc, RFLP with metastasis prognosis an multiple cancer in lung cancer paients. Int. J. Cancer. 50:1992;557-561.
30. Kern J.A., Schwartz D.A., Nordberg J.E., Weiner D.B., Greene M.I., Torney L. et al. P185 neu expression in human lung adenocarcinomas predicts shortened survival. Cancer. Res. 50:1990;5184-5191.
31. Shi D., He G., Cao S.L., Pan W., Zhang H.Z., Yu D. et al. Overexpression of the c-erb B2/neu encoded p185 protein in primary lung cancer. Mol. Carcinogen. 5:1992;213-218.
32. Fung C.Y., Fisher D.E. p53: from molecular mechanisms to prognosis in cancer. J. Clin. Oncol. 13:1995;808-811.
33. Carbone D.P., Mitsudomi T., Chiba H., Piantadosi S., Rusch V., Nouwak J.A. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutation in resected non-small cell lung cancer. Chest. 106/6:1994;377s-381.
34. Horio Y., Takanashi T., Kuroish T., Hibi K., Suyama M., Niimi T. et al. Prognostic significance of p53 mutations and 3p deletion in primary resected non-small cell lung cancer. Cancer. Res. 53:1993;1-4.
35. Quinlan D.C., Davidson A.G., Summers C.L., Warden H., Doshi H.M. et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer. Res. 52:1992;4828-4831.
36. Marchetti A., Buttitta F., Merlo G., Diella F., Pellegrini S., Pepe S. et al. p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hila and mediastinal lymph nodes. Cancer. Res. 53:1993;2846-2851.
37. McLaren R., Kuzu T., Dunnill M., Harris A., Lane D., Gatter K.C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer. 66:1992;735-738.
38. Top B., Mooi W., Klaver S.G., Boerrigater L., Wisman P., Elbers H.R. et al. Comparative analysis of p53 gene mutations and protein accumulation in human non-small cell lung cancer. Int. J. Cancer. 64(2):1995;83-91.
39. Morkve O., Halversen O.J., Skjaerven R., Stangeland L., Gulsvik A., Laerum O.D. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung cancer. Anticancer. Res. 13:1993;571-578.
40. Lee J.S., Yoon A., Kalapurakal S.K., Ro J.Y., Lee J.J., Tu N. et al. Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J. Clin. Oncol. 13(8):1995;1893-1903.
41. Campos L., Guyotat D., Achimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J. et al. Clinical significance of multidrug resistance p-glycoprotein on acute non-lymphoblastic leukemia cells at diagnosis. Blood. 79:1992;473-476.
42. Dalquen P., Sauter G., Torhorst J., Schultheiss L., Jordan P., Lehmann S. et al. Nuclear p53 overexpression is an independent prognostic , parameter in node-negative non-small cell lung carcinoma. J. Pathol. 178:1996;53-58.
43. Fujino M., Dosaka H., Harada M., Hiroami H., Kinoshita L., Akie K. et al. Prognostic significance of p53 and ras p21 in non-small cell lung cancer. Cancer. 76:1995;2457-2463.
44. Harmsel B.T., Smedts F., Kuijpers J., Jeunink M., Trimbos B., Ramackers F. Bel-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CNI and cervical carcinoma. J. Pathol. 179:1996;26-30.
45. Khalid H., Yasunaga A., Kishikawa J., Shibata S. Immunohistochemical expression of the estrogen receptor-related antigen (ER-D5) in human intracranial tumors. Cancer. 75(10):1995;2571-2578.
46. Leonardo E., Valente G., Cappia S., Cianfriglia M., Arancia G., Meschini S. et al. Immunohistochemical evaluation of p-glycoprotein in human malignancies by monoclonal antibody MC57. Int. J. Cancer. 57:1994;841-845.
47. Nakopoulou L.L., Alexiadou A., Theodoropoulos C.E. Prognostic significance of the co-expression of p53 and c-erb-B-2 proteins in breast cancer. J. Pathol. 179:1996;31-38.
48. Balmain A., Brown K. Oncogene activation in chemical carcinogenesis. Adv. Cancer. Res. 51:1988;147-182.
49. Roussel M.F., Cleveland J.L., Shurtleff S.A., Sherr C.J. Myc reassure of a mutant csf-receptor impaired in mitogenic signaling. Nature. 353(6342):1991;361-363.
50. Dosaka-Akita H., Hu S.X., Fujino M., Harda M., Kinoshita I., Xu H.J. et al. Altered retinoblastoma protein expression in non-small cell lung cancer its synergistic effects with alterated ras and P53 protein statues on prognosis. Cancer. 79(7):1997;1329-1337.
51. Harpole D.H. Jr., Herndon J.E., Wolfe G.L., Iglehart J.D., Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer. Res. 55(1):1995;51-56.